Rocket Pharmaceuticals
rocketpharma.com · Healthcare · RCKT
Ranked 1,503 of 2,047 companies in the study
- Visibility0
- Citations1
- Sentiment50
- Site quality87
- AI readiness29
AI assistants do not name Rocket Pharmaceuticals in any of their 60 answers. Its overall score is 28 out of 100, which ranks 1,503rd of 2,047 companies and 64th of 105 in its sector. The company's website passes 4 of 14 technical checks on readiness for AI tools.
We asked 15 unbranded questions about the healthcare market: none named Rocket Pharmaceuticals. AI assistants named it in none of 60 answers. The typical healthcare company is named in 3.3% of answers. By how often it is named, Rocket Pharmaceuticals ranks 69 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
The company is not named in this answer
“Best gene therapy treatments currently in clinical trials for pediatric patients with inherited metabolic disorders”
Gene therapy is rapidly advancing as a transformative treatment option for pediatric patients with inherited metabolic disorders (IMDs), many of which are rare and debilitating with limited therapeutic options. This approach aims to correct the underlying genetic cause of these diseases by introducing a functional copy of a defective gene or editing the faulty gene itself.
Here are some of the best gene therapy treatments currently in clinical trials or recently approved for pediatric patients with IMDs:
Recently Approved Gene Therapies:
Sanfilippo Syndrome Type A (MPS IIIA): Fa …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Not by itself. Rocket Pharmaceuticals publishes none of the purchase protocols we look for. An agent would have to click through the checkout like a person.
- UCPNot present
- ACPNot present
- AP2Not present
- x402Not present
- MPPNot present
The shop runs on WooCommerce.
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPartly met
Serve an XML sitemap and reference it from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 24 of 100 · 97% of checks could run · checked on October 5, 2026 · rocketpharma.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- Who might benefit most from gene therapy aimed at correcting the genetic root cause of disease?
- How do specialists monitor patients for immune reactions after receiving gene therapy for inherited diseases?
- Is gene therapy for rare genetic disorders worth considering compared to lifelong symptom management?
- Are there financial assistance programs available for patients seeking gene therapy for rare conditions?
- Alternatives to gene therapy for treating rare genetic diseases affecting adolescents
- What should families consider before enrolling a child in a gene therapy clinical trial for rare disease?
- How is gene therapy administered to patients with rare monogenic disorders?
- What non-gene therapy treatment options are available for rare cardiac genetic disorders?
- How does gene therapy for Danon disease compare to traditional enzyme replacement therapy?
- Gene therapy vs. stem cell transplantation for treating rare neuromuscular genetic diseases
- How much does gene therapy typically cost for rare hereditary diseases in the United States?
- Best gene therapy treatments currently in clinical trials for pediatric patients with inherited metabolic disorders
- What are the most promising gene therapy options for rare genetic diseases affecting the heart?
- What are common side effects of gene therapy targeting cardiac tissue in rare disorders?
- Other approaches besides gene therapy being developed for rare, inherited metabolic diseases
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.